idiopath
dilat
cardiomyopathi
idc
account
case
heart
failur
unit
state
understand
relationship
incit
event
agent
develop
idc
progress
recent
idc
develop
treatment
palli
littl
done
alter
natur
cours
diseas
activ
myocard
suspect
precursor
idc
myocardi
inflamm
injuri
without
ischemia
diseas
rang
selflimit
flulik
ill
one
seriou
consequ
arrhythmia
heart
failur
death
mani
agent
associ
myocard
clinic
manifest
depend
interplay
incit
agent
host
respons
develop
murin
model
expand
use
endomyocardi
biopsi
use
dalla
criteria
increas
understand
myocard
sequela
therapi
consist
manag
symptom
use
convent
medic
regimen
heart
failur
immunosuppress
therapi
reserv
patient
biopsyproven
diseas
fail
convent
therapi
continu
deterior
warrant
ventricular
assist
consider
cardiac
transplant
ore
million
peopl
unit
state
affect
heart
failur
new
case
diagnos
death
year
econom
effect
great
expenditur
approxim
billion
dollar
repres
feder
health
care
dollar
spent
year
true
impact
addit
disabl
loss
product
yet
calcul
idiopath
dilat
cardiomyopathi
idc
name
left
ventricular
dilat
systol
dysfunct
absenc
coronari
valvular
congenit
heart
diseasesaccount
case
progress
recent
made
howev
understand
relationship
incit
event
agent
develop
idc
regrett
develop
treatment
palli
littl
done
alter
natur
histori
precipit
factor
persist
activ
myocard
suspect
common
precursor
idc
defin
inflamm
injuri
myocardium
absenc
ischemia
spectrum
diseas
vari
benign
selflimit
flulik
ill
one
seriou
consequ
manifest
arrhythmia
heart
failur
death
mani
agent
tabl
associ
activ
myocard
clinic
manifest
depend
interplay
incit
event
agent
host
respons
progress
made
understand
mechan
result
clinic
diseas
focu
intens
investig
myocardi
injuri
may
result
one
follow
myocyt
infect
replic
offend
agent
result
cellular
destruct
destruct
due
activ
cellular
humor
defens
mechan
trigger
infecti
agent
exogen
toxin
produc
pathogen
coronari
endotheli
invas
result
microvascular
pathogenesi
woodruff
report
myocardi
infect
occur
coxsackieviru
commonli
identifi
caus
human
myocard
immunocompet
host
inject
weanl
mice
replic
viru
obtain
day
inocul
evid
heart
failur
absent
phase
histolog
evid
intlamm
histolog
examin
swiss
icr
mice
infect
month
earlier
show
persist
inflamm
earli
sign
heart
failur
month
histolog
evid
inflamm
although
heart
failur
develop
mural
thrombosi
left
ventricular
dilat
data
obtain
murin
model
impli
myocardi
damag
occur
two
phase
first
acut
phase
involv
myocardi
cell
infect
replic
cell
lysi
viru
clear
macrophag
natur
killer
cell
neutral
antibodi
second
chronic
phase
involv
myocardi
infiltr
inflammatori
cell
product
cardiotrop
antibodi
myocardi
damag
may
minim
sever
figur
viral
clearanc
unaffect
acut
phase
antithymocyt
serum
administ
balbc
mice
progress
intiammatori
respons
cellmedi
immun
respons
rather
humor
import
chronic
myocyt
injuri
dysfunct
develop
autoantibodi
greceptor
myosin
adenosin
diphosphateadenosin
triphosph
adpatp
carrier
protein
cm
thu
viral
infect
although
clinic
quiescent
trigger
autoimmun
cellular
possibl
humor
respons
lead
myocardi
inflamm
necrosi
eventu
culmin
pathophysiolog
state
similar
idc
myocard
lead
idc
murin
model
observ
increas
enterovir
antibodi
titer
patient
myocard
idc
tradit
offer
evid
enterovirus
caus
agent
unfortun
enterovir
infect
common
gener
popul
difficult
ascertain
acut
convalesc
titer
coincid
onset
heart
dysfunct
fletcher
found
patient
idc
coxsackieviru
b
viral
titer
unfortun
incid
found
control
cambridg
found
level
viral
titer
use
cutoff
point
increas
patient
abnorm
level
oppos
control
similar
result
obtain
kitaur
japan
found
significantli
greater
proport
patient
idc
coxsackieviru
bl
titer
greater
compar
control
two
studi
suggest
patient
idc
greater
preval
coxsackieviru
b
infect
gener
popul
hand
infect
cardiotrop
virus
extrem
common
adult
expos
may
even
experienc
subclin
myocard
yet
develop
idc
despit
compel
data
associ
enterovir
infect
myocard
bowl
archard
report
coxsackiegenom
sequenc
detect
use
probe
slotblot
hybrid
human
heart
biopsyproven
activ
heal
myocard
idc
although
question
specif
probe
aros
make
data
difficult
interpret
first
studi
implic
persist
enteroviru
sever
investig
use
situ
hybrid
detect
enterovir
genom
myocardi
tissu
suggest
patient
myocard
may
myocardi
enterovir
intrigu
question
left
unansw
date
capabl
genom
replic
intact
virus
demonstr
suggest
genom
nonrepl
defect
viral
fragment
may
immunogen
mere
marker
previou
infect
answer
await
studi
investig
suggest
microvascular
spasm
may
play
role
develop
myocardi
damag
hypothesi
endotheli
cell
infect
damag
result
immun
respons
lead
microvascular
abnorm
sole
suggest
repetit
cycl
microvascular
spasm
lead
dissolut
myocardi
matrix
multifoc
loss
cardiac
muscl
ultim
lead
myocardi
failur
precis
role
microvascular
spasm
impact
develop
myocard
yet
unresolv
clinic
express
myocard
spectrum
diseas
rang
asymptomat
state
progress
deterior
cardiac
function
ultim
death
occasion
patient
may
present
acut
unexplain
heart
failur
diagnosi
suspect
common
etiolog
exclud
natur
histori
diseas
poorli
describ
unpredict
patient
complet
resolut
symptom
suffer
sequela
other
progress
fulmin
heart
failur
develop
heart
failur
may
first
clinic
manifest
typic
occur
late
diseas
clinic
indistinguish
idc
sudden
death
may
also
earli
manifest
myocard
occur
stage
diseas
exact
time
infect
cardiac
dysfunct
variabl
complaint
present
may
includ
fatigu
short
breath
dyspnea
exert
palpit
precordi
flulik
syndrom
often
anted
cardiac
symptom
usual
forgotten
patient
physic
examin
nonspecif
frequent
unrev
tachycardia
proport
heart
failur
common
distant
heart
sound
transient
gallop
systol
murmur
may
present
fulmin
case
reveal
find
consist
heart
failur
fever
leukocytosi
elev
erythrocyt
sediment
rate
frequent
nonspecif
laboratori
iind
tabl
ii
lg
variabl
transient
electrocardiograph
chang
may
note
stsegment
twave
abnorm
frequent
rhythm
disturb
includ
atrial
ventricular
arrhythmia
common
conduct
defect
common
patient
left
bundl
branch
although
usual
transient
without
sequela
atrioventricular
block
caus
sudden
death
patient
acut
myocard
patient
clinic
heart
failur
myocard
nonspecif
find
left
ventricular
systol
dysfunct
enlarg
left
ventricular
caviti
size
increas
wall
thick
wall
motion
abnorm
may
seen
echocardiographi
left
ventricular
thrombi
detect
patient
radiograph
find
rang
normal
heart
size
cardiomegali
pulmonari
congest
seen
sever
case
radionuclid
scan
use
antimyosin
antibodi
may
reveal
inflamm
necrosi
suggest
myocard
test
lack
necessari
sensit
specif
appli
screen
toolszo
patient
experi
clinic
syndrom
consist
myocardi
infarct
typic
chest
pain
stt
segment
chang
wall
motion
abnorm
enzym
alter
even
qwave
develop
normal
coronari
arteri
angiograph
patient
endomyocardi
biopsi
may
appropri
confirm
myocarditisassoci
necrosi
diagnosi
myocard
may
suggest
clinic
manifest
frequent
follow
etiolog
rule
readili
consid
young
previous
healthi
patient
problemat
older
patient
multipl
comorbid
ill
may
predispos
result
cardiac
dysfunct
frequent
patient
undergo
exhaust
workup
culmin
angiographi
myocardi
biopsi
diagnosi
made
serolog
evid
fourfold
rise
viral
neutral
complement
fixat
hemagglutinationinhibit
titer
support
confirmatori
diagnosi
viral
myocard
viru
may
occasion
cultur
stool
blood
urin
throat
wash
suggest
caus
agent
confirmatori
evid
activ
myocard
establish
endomyocardi
biopsi
right
ventricular
biopsi
right
intern
jugular
femoven
approach
prefer
cardiologist
left
ventricular
biopsi
may
warrant
howev
suspicion
myocard
high
right
ventricular
biopsi
confirm
activ
myocard
suspect
sampl
error
although
endomyocardi
biopsi
use
idc
suspect
case
myocard
prior
lack
histolog
standard
frequent
led
differ
interpret
individu
pathologist
prepar
multicent
myocard
treatment
trial
group
expert
pathologist
conven
consensu
confer
establish
dalla
criteria
criteria
defin
inflammatori
heart
diseas
activ
myocard
borderlin
myocard
myocard
activ
myocard
defin
myocardi
leukocyt
infiltr
necrosi
absenc
ischemia
borderlin
myocard
involv
infiltr
without
necrosi
specif
diagnosi
made
inflammatori
cell
seen
adopt
dalla
criteria
led
concord
among
experienc
pathologist
although
myocard
rule
biopsi
sampl
error
patient
focal
diseas
diagnosi
made
high
degre
confid
primari
focu
initi
manag
idc
relief
symptom
heart
failur
tabl
iii
patient
volum
overload
treat
diuret
sodium
water
restrict
angiotensinconvert
enzym
ace
inhibitor
initi
patient
systol
dysfunct
toler
agent
north
scandinavian
enalapril
surviv
studi
consensu
show
patient
new
york
heart
associ
class
iii
iv
symptom
improv
surviv
treat
enalapril
studi
left
ventricular
dysfunct
solvd
studi
show
patient
less
sever
diseas
also
patient
intoler
ace
inhibit
veteran
heart
failur
trial
vehft
ii
conclud
hydralazin
isosorbid
dinitr
combin
improv
outcom
lesser
degre
ace
inhibit
may
import
digitali
glycosid
commonli
administ
although
close
monitor
necessari
avoid
digitali
toxic
refractori
patient
shortterm
use
dobutamin
may
benefici
murin
model
forc
physic
activ
enhanc
myocyt
necrosi
inflammatori
respons
result
increas
mortal
even
though
confiiatori
studi
perform
man
wise
restrict
physic
activ
decis
treat
ventricular
arrhythmia
lifethreaten
complic
may
occur
even
minim
left
ventricular
dysfunct
difficult
myocard
may
resolv
spontan
respond
immunosuppress
reduct
risk
antiarrhythm
agent
immunosuppress
therapi
substanti
side
effect
myocard
persist
rational
antiarrhythm
agent
clearer
treatment
automat
implant
cardiovert
defibril
amiodaron
reserv
lifethreaten
situat
high
likelihood
spontan
improv
corticosteroid
frequent
use
treatment
myocard
benefit
unproven
preliminari
studi
follow
expand
applic
endomyocardi
biopsi
detect
cardiac
allograft
reject
includ
patient
unexplain
heart
failur
result
therapeut
dilemma
clinician
interest
increas
therapeut
modal
modifi
immun
mechan
felt
respons
inflamm
identifi
biopsi
corticosteroid
immunosuppress
drug
report
benefici
patient
biopsi
posit
myocard
although
studi
uncontrol
therapi
standard
optimist
result
enhanc
broad
use
immunosuppress
drug
activ
myocard
nibsponsor
multicent
myocard
treatment
trial
establish
evalu
efficaci
immunosuppress
treatment
activ
myocard
patient
eject
fraction
unexplain
heart
failur
biopsyproven
myocard
dalla
criteria
random
convent
treatment
heart
failm
alon
convent
treatment
prednison
combin
cyclosporin
azathioprin
patient
observ
month
random
drug
treatment
anoth
month
convent
treatment
alon
fmal
evalu
year
figur
enrol
began
complet
eject
fraction
exercis
treadmil
test
endomyocardi
biopsi
right
heart
hemodynanuc
electrocardiogram
ambulatori
monitor
echocardiographi
perform
baselin
week
peripher
blood
collect
lymphocyt
subset
natur
kiher
cell
activ
antibodydepend
cellular
cytotox
humor
antibodi
endomyocardi
biopsi
studi
lymphocyt
subset
antibodi
enterovir
genom
result
trial
current
analyz
shed
light
efficaci
immunosuppress
see
addendum
time
immunosuppress
recommend
unless
patient
deterior
rapidli
despit
convent
medic
manag
patient
experi
continu
hemodynam
deterior
despit
maxim
pharmacolog
maneuv
substanti
percentag
patient
potenti
revers
condit
kept
aliv
mechan
ventricular
assist
regrett
clinic
indic
biopsi
find
immunolog
test
laboratori
find
sever
hemodynam
dysfunct
assist
predict
eventu
outcom
likelihood
spontan
recoveri
cardiac
transplant
consid
patient
progress
refractori
heart
failur
show
benefit
trial
immunosuppress
nevertheless
high
spontan
recoveri
rate
even
extrem
degre
left
ventricular
decompens
prompt
recommend
prolong
mechan
support
necessari
adequ
time
recoveri
consid
transplant
unfortun
patient
undergo
transplant
activ
myocard
lyear
surviv
poorer
patient
transplant
reason
versu
respect
reject
rate
twice
control
recipi
poor
outcom
follow
transplant
may
due
intens
immunolog
activ
target
cardiac
antigen
prior
transplant
predispos
earli
reject
beyond
earli
posttransplant
period
surviv
rate
indistinguish
recipi
develop
murin
model
expand
use
endomyocardi
biopsi
use
dalla
criteria
broaden
understand
myocard
sequela
high
index
suspicion
clinician
essenti
correct
diagnosi
numer
test
avail
support
diagnosi
endomyocardi
biopsi
remain
gold
standard
therapi
direct
toward
manag
symptom
use
convent
medic
regimen
heart
failur
although
controversi
immunosuppress
therapi
reserv
patient
biopsyproven
diseas
fail
convent
therapi
continu
deterior
warrant
ventricular
assist
consider
cardiac
transplant
elucid
use
endomyocardi
biopsi
immunosuppress
therapi
await
final
result
myocard
treatment
trial
undoubtedli
advanc
understand
pathophysiolog
greatest
impact
alter
diseas
process
sinc
accept
manuscript
myocard
treatment
trial
result
report
investig
could
demonstr
differ
outcom
patient
receiv
immunosuppress
public
result
alter
conclus
manuscript
